€90.70
4.32%
Paris, Apr 17, 05:35 pm CET
ISIN
FR0010259150
Symbol
IPN
Sector
Industry

Ipsen Stock price

€90.70
-20.40 18.36% 1M
-26.10 22.35% 6M
-20.00 18.07% YTD
-15.70 14.76% 1Y
-23.60 20.65% 3Y
+35.20 63.42% 5Y
+45.26 99.58% 10Y
Paris, Closing price Thu, Apr 17 2025
-4.10 4.32%
ISIN
FR0010259150
Symbol
IPN
Sector
Industry

Key metrics

Market capitalization €7.50b
Enterprise Value €7.34b
P/E (TTM) P/E ratio 21.68
EV/FCF (TTM) EV/FCF 10.00
EV/Sales (TTM) EV/Sales 2.16
P/S ratio (TTM) P/S ratio 2.21
P/B ratio (TTM) P/B ratio 1.79
Dividend yield 1.54%
Last dividend (FY24) €1.40
Revenue growth (TTM) Revenue growth 8.73%
Revenue (TTM) Revenue €3.40b
EBIT (operating result TTM) EBIT €1.10b
Free Cash Flow (TTM) Free Cash Flow €734.30m
EPS (TTM) EPS €4.18
P/E forward 11.17
P/S forward 2.02
EV/Sales forward 1.97
Show more

Is Ipsen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Ipsen Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Ipsen forecast:

6x Buy
38%
8x Hold
50%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Ipsen forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Ipsen

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
3,401 3,401
9% 9%
100%
- Direct Costs 619 619
8% 8%
18%
2,782 2,782
9% 9%
82%
- Selling and Administrative Expenses 586 586
8% 8%
17%
- Research and Development Expense 687 687
11% 11%
20%
1,510 1,510
16% 16%
44%
- Depreciation and Amortization 414 414
31% 31%
12%
EBIT (Operating Income) EBIT 1,096 1,096
12% 12%
32%
Net Profit 346 346
46% 46%
10%

In millions EUR.

Don't miss a Thing! We will send you all news about Ipsen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; and Fortrans, a colon cleansing solution indicated for patients in preparation for endoscopic, radiological examinations or colonic surgery. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Head office France
CEO David Loew
Employees 5,358
Founded 1998
Website www.ipsen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today